TCTR20230117005招募中4 期
Recombinant human erythropoietin increasing hemoglobin level and reducing blood transfusion in femoral fracture patients, a randomized controlled trial study
Faculty of medicine vajira hospital0 个研究点目标入组 50 人开始时间: 2023年1月17日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15 Years 至 80 Years（—）
- 性别
- All
入选标准
- •Femoral fracture patients age 15 - 80 years old who underwent surgical intervention
排除标准
- •1. patients with hemoglobin less than 9 g/dL, greater than 16 g/dL, 2.on antiplatelets drugs, 3.known case bone marrow disease etc thalassemia, myelodysplastic syndrome, multiple myeloma 4.Chronic kidney disease, 5.Allergy if EPO, 6.Contraindicated for EPO, 7.Severe traumatic brain injury
研究者
相似试验
已完成
不适用
Recombinant human erythropoietin therapy in critically ill patients: a dose response studyCritically ill patients with anaemiaHaematological DisordersAnaemiaISRCTN48523317Janssen-Cilag (Greece)148
尚未招募
不适用
Effect of recombinant human erythropoietin administration before cardiopulmonary bypass on the development of postoperative acute kidney injury in patients undergoing valvular heart surgeryDiseases of the circulatory systemKCT0000696Asan Medical Center228
尚未招募
3 期
Erythropoietin for Perinatal asphyxiaCTRI/2018/04/013331Dr Atul Londhe
已完成
4 期
Impact of Recombinant Human Erythropoietin (ior EPO-CIM) in oncology pediatric patients with post chemo and /or radiotherapy.Anemia secondary to chemo and/or radiotherapy.RPCEC00000080Center of Molecular Immunology(CIM)161
已完成
1 期
The benefits of Erythropoietin in reducing the need for blood transfusions in patients receiving chemotherapysolid insitu tumor of the body.In situ neoplasmsD00-D09IRCT2015061822805N1Vice Chancellor for research of Tabriz University of Medical Sciences60